지역사회 획득 폐렴 시장 - 세계 및 지역/국가별 분석과 예측(2025-2035년)

Global Community-Acquired Bacterial Pneumonia Market, Analysis and Forecast: 2025-2035

Community-acquired bacterial pneumonia (CABP) is an infection of the lungs caused by bacteria that is contracted outside of a healthcare setting. It is one of the most common types of pneumonia and typically occurs when bacteria enter the lungs through the respiratory tract, leading to inflammation and infection in the lung tissue. The most common pathogens responsible for community-acquired bacterial pneumonia include Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis, though other bacteria can also cause the disease.

Symptoms of community-acquired bacterial pneumonia often include fever, cough, chest pain, difficulty breathing, and fatigue. The infection can range from mild to severe and may require hospitalization, particularly in vulnerable populations such as the elderly, those with chronic conditions, or individuals with compromised immune systems. Early diagnosis and treatment with appropriate antibiotics are crucial to prevent complications such as respiratory failure or sepsis. Prevention strategies include vaccination, good hygiene practices, and smoking cessation. With proper medical management, the prognosis for community-acquired bacterial pneumonia is generally favourable, although recovery may be prolonged in severe cases or for those with underlying health conditions.

Community-acquired pneumonia (CAP), particularly bacterial, is one of the leading causes of morbidity and mortality worldwide. In the U.S. alone, community-acquired pneumonia affects an estimated 5 to 6 million people each year, with hospitalization rates reaching 20-30% among adults. The Global Burden of Disease Study also highlights that pneumonia results in more than 100 million cases globally each year, with bacterial pathogens, particularly Streptococcus pneumoniae, being the most prevalent. This high and growing prevalence acts as a primary driver for the market, necessitating more effective diagnostics, treatment options, and preventive strategies.

Significant investments in healthcare infrastructure worldwide are playing a crucial role in driving the community-acquired bacterial pneumonia market. Governments and private sector stakeholders are continuously enhancing hospital facilities, expanding intensive care capabilities, and improving diagnostic technologies. For instance, OECD countries reported an average healthcare spending of around 9.7% of GDP in 2022, reflecting a sustained focus on strengthening health systems. In emerging economies such as India, public health expenditure rose to 2.1% of GDP in 2023, with major portions allocated to infectious disease control and emergency preparedness. Such infrastructural investments ensure timely diagnosis, advanced patient management, and broader accessibility to antibiotics and vaccines. This trend not only improves patient outcomes but also fuels demand for related therapeutics, diagnostics, and supportive care solutions, thereby expanding the overall market.

Despite these advances, the community-acquired bacterial pneumonia market faces several challenges. The high cost associated with the distribution and development of drugs is a significant constraint within the community-acquired bacterial pneumonia market. The process of developing new antibiotics and therapies requires substantial financial investment in research and development (R&D), clinical trials, and regulatory approvals. This is particularly true for antibiotics targeting resistant bacterial strains, which necessitate advanced research techniques and specialized production processes. The costs associated with manufacturing, quality control, and distribution further exacerbate the financial burden. These factors often result in limited market access, particularly in low-income regions or for patients with inadequate insurance coverage. Additionally, pharmaceutical companies face the challenge of balancing the need for profitability with the substantial costs of bringing a new drug to market, which can result in delays and reduced availability of innovative treatments, ultimately inhibiting the growth of the community-acquired bacterial pneumonia market.

The global community-acquired bacterial pneumonia market is highly competitive, with several leading companies driving innovation and growth, such as Nabriva Therapeutics, Paratek Pharmaceuticals, Eagle Pharmaceutical, Pfizer, Inc., and Merck & Co. Companies in the community-acquired bacterial pneumonia (CABP) market are adopting key strategies to boost growth. One approach is focusing on developing innovative drugs, especially targeting antibiotic-resistant bacteria, to meet unmet medical needs. Firms are also investing heavily in research and development to create more effective and broad-spectrum antibiotics and to improve drug delivery systems. To expand their market presence, companies are forming strategic partnerships and collaborations with research institutions, biotechnology firms, and other pharmaceutical firms to leverage expertise and accelerate product development.

Community-Acquired Bacterial Pneumonia Market Segmentation:

Segmentation 1: by Region

• North America
• Europe
• Asia-Pacific

The global community-acquired bacterial pneumonia market is undergoing significant transformation, fuelled by emerging opportunities that are reshaping treatment paradigms and driving community-acquired bacterial pneumonia market growth. The growing number of drug approvals and launches in the community-acquired bacterial pneumonia market presents a promising opportunity for growth. Regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have been fast-tracking approvals for innovative antibiotics and therapies, especially those that target multidrug-resistant bacteria. As antibiotic resistance continues to rise globally, there is an increasing need for new, more effective treatments. The approval of new drugs provides pharmaceutical companies with the opportunity to capitalize on unmet medical needs by introducing more effective and targeted therapies for community-acquired bacterial pneumonia.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Community-Acquired Bacterial Pneumonia Market: Industry Analysis

• 1.1 Market Overview and Ecosystem
• 1.2 Epidemiological Analysis
• 1.3 Key Market Trends
  • 1.3.1 Impact Analysis
• 1.4 Regulatory Landscape
• 1.5 Pipeline Analysis
• 1.6 Market Dynamics
  • 1.6.1 Overview
  • 1.6.2 Market Drivers
  • 1.6.3 Market Restraints
  • 1.6.4 Market Opportunities

2. Global Community-Acquired Bacterial Pneumonia Market (by Region), Value ($Million), 2024-2035

• 2.1 North America
  • 2.1.1 Market Dynamics
  • 2.1.2 Market Sizing and Forecast
  • 2.1.3 North America Community-Acquired Bacterial Pneumonia Market, by Country ($Million), 2024-2035
    • 2.1.3.1 U.S.
• 2.2 Europe
  • 2.2.1 Market Dynamics
  • 2.2.2 Market Sizing and Forecast
  • 2.2.3 Europe Community-Acquired Bacterial Pneumonia Market, by Country ($Million), 2024-2035
    • 2.2.3.1 U.K.
    • 2.2.3.2 France
    • 2.2.3.3 Germany
    • 2.2.3.4 Italy
    • 2.2.3.5 Spain
• 2.3 Asia-Pacific
  • 2.3.1 Market Dynamics
  • 2.3.2 Market Sizing and Forecast
  • 2.3.3 Asia-Pacific Community-Acquired Bacterial Pneumonia Market, by Country ($Million), 2024-2035
    • 2.3.3.1 Japan

3. Competitive Landscape and Company Profiles

• 3.1 Competitive Landscape
  • 3.1.1 Mergers and Acquisitions
  • 3.1.2 Partnership, Alliances and Business Expansion
  • 3.1.3 New Offerings
  • 3.1.4 Regulatory Activities
  • 3.1.5 Funding Activities
• 3.2 Company Profiles
  • 3.2.1 Nabriva Therapeutics.
    • 3.2.1.1 Overview
    • 3.2.1.2 Top Products / Product Portfolio
    • 3.2.1.3 Top Competitors
    • 3.2.1.4 Target Customers/End-Users
    • 3.2.1.5 Key Personnel
    • 3.2.1.6 Analyst View
  • 3.2.2 Paratek Pharmaceuticals
    • 3.2.2.1 Overview
    • 3.2.2.2 Top Products / Product Portfolio
    • 3.2.2.3 Top Competitors
    • 3.2.2.4 Target Customers/End-Users
    • 3.2.2.5 Key Personnel
    • 3.2.2.6 Analyst View
  • 3.2.3 Eagle Pharmaceutical.
    • 3.2.3.1 Overview
    • 3.2.3.2 Top Products / Product Portfolio
    • 3.2.3.3 Top Competitors
    • 3.2.3.4 Target Customers/End-Users
    • 3.2.3.5 Key Personnel
    • 3.2.3.6 Analyst View
  • 3.2.4 Merck & Co.
    • 3.2.4.1 Overview
    • 3.2.4.2 Top Products / Product Portfolio
    • 3.2.4.3 Top Competitors
    • 3.2.4.4 Target Customers/End-Users
    • 3.2.4.5 Key Personnel
    • 3.2.4.6 Analyst View
  • 3.2.5 Pfizer Inc.
    • 3.2.5.1 Overview
    • 3.2.5.2 Top Products / Product Portfolio
    • 3.2.5.3 Top Competitors
    • 3.2.5.4 Target Customers/End-Users
    • 3.2.5.5 Key Personnel
    • 3.2.5.6 Analyst View
  • 3.2.6 Takeda Pharmaceutical Company Limited. (TiGenix)
    • 3.2.6.1 Overview
    • 3.2.6.2 Top Products / Product Portfolio
    • 3.2.6.3 Top Competitors
    • 3.2.6.4 Target Customers/End-Users
    • 3.2.6.5 Key Personnel
    • 3.2.6.6 Analyst View
  • 3.2.7 Melinta Therapeutics LLC.
    • 3.2.7.1 Overview
    • 3.2.7.2 Top Products / Product Portfolio
    • 3.2.7.3 Top Competitors
    • 3.2.7.4 Target Customers/End-Users
    • 3.2.7.5 Key Personnel
    • 3.2.7.6 Analyst View
  • 3.2.8 Allergan Plc.
    • 3.2.8.1 Overview
    • 3.2.8.2 Top Products / Product Portfolio
    • 3.2.8.3 Top Competitors
    • 3.2.8.4 Target Customers/End-Users
    • 3.2.8.5 Key Personnel
    • 3.2.8.6 Analyst View
  • 3.2.9 Theravance Biopharma Inc.
    • 3.2.9.1 Overview
    • 3.2.9.2 Top Products / Product Portfolio
    • 3.2.9.3 Top Competitors
    • 3.2.9.4 Target Customers/End-Users
    • 3.2.9.5 Key Personnel
    • 3.2.9.6 Analyst View
  • 3.2.10 Pfizer, Inc.
    • 3.2.10.1 Overview
    • 3.2.10.2 Top Products / Product Portfolio
    • 3.2.10.3 Top Competitors
    • 3.2.10.4 Target Customers/End-Users
    • 3.2.10.5 Key Personnel
    • 3.2.10.6 Analyst View
  • 3.2.11 Others

4. Research Methodology